Sunitinib and Cyclophosphamide in Advanced Renal Cell Carcinoma

• Research type

  Research Study

• Full title

  A Phase II Study Of Sunitinib And Low Dose Metronomic Cyclophosphamide In Advanced Renal Cell Cancer

• IRAS ID

  9477

• Eudract number

  2008-008676-13

• ISRCTN Number

  N/A

• Clinicaltrials.gov Identifier

  N/A

• Research summary

  Sunitinib is a standard treatment for advanced renal cell carcinoma but only 75% of patients will benefit from this treatment and the average duration of benefit is approximately a year. Sunitinib works by attacking blood vessels in tumours and the aim of this study is to investigate the combination of sunitinib with another drug, low dose cyclophosphamide, that is thought to attack blood vessels in a different way.

• REC name

  London - Chelsea Research Ethics Committee

• REC reference

  09/H0801/5

• Date of REC Opinion

  25 Feb 2009

• REC opinion

  Favourable Opinion